Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.26 USD | +1.45% | -1.07% | -3.38% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.38% | 9.6B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Transcript : Qiagen N.V. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01